TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation
TAIPEI, Sept. 11, 2024 /PRNewswire/ -- TCI Co. Ltd. ("TCI", 8436.TWO), a global leader in ODM health and cosmetic products for over 40 years, introduces its cutting-edge GLP-1 formula, a natural blend of plant extracts, probiotics, and prebiotics designed to deliver powerful weight management results. The global obesity crisis continues to surge. In 2022, the WHO reported over one...
Adequate legal assistance funding is vital to improving health and wellbeing outcomes
SYDNEY, Sept. 11, 2024 /PRNewswire/ -- Health Justice Australia has welcomed last week's announcement that the Australian Government will provide $3.9 billion in funding to the legal assistance sector through the new National Access to Justice Partnership. Commencing in July 2025, this agreement delivers funding for frontline legal assistance services including community legal centres, Aboriginal and Torres Strait Islander...
PRODUCTLIFE GROUP ACQUIRES OUTCOMES’10, EXPANDING EUROPEAN MARKET ACCESS CAPABILITIES
PARIS, Sept. 11, 2024 /PRNewswire/ -- ProductLife Group (PLG), a global provider of regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is pleased to announce the acquisition of Outcomes'10, a premier Spanish life sciences consultancy providing patient access and evidence generation services. Founded 15 years ago, Outcomes'10 is a trusted partner for its comprehensive...
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue
Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the current state of antiviral treatments at the "Disease Prevention...
TTLife Oxygen Concentrator: A VARON-Certified Dealer, Your Reliable Partner in First Aid Preparedness
LOS ANGELES, Sept. 11, 2024 /PRNewswire/ -- TTLife Oxygen Concentrator, is proud to announce its certification as a VARON-certified dealer of oxygen concentrators. This recognition solidifies TTLife's commitment to delivering high-quality, reliable, safe medical equipment. As we approach World First Aid Day on September 14, 2024, TTLife urges everyone to prioritize first aid preparedness. With the increasing prevalence of...
GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia
YONGIN, South Korea, Sept. 11, 2024 /PRNewswire/ -- GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bifarma Adiluhung (Bifarma), a premier stem cell therapy company in Indonesia. This strategic partnership, which began in June, solidifies approximately three months...
Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC
SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the presentation of Phase 1 clinical data (ClinicalTrials.gov, NCT04085185) for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in...
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
SHANGHAI, Sept. 11, 2024 /PRNewswire/ -- Nuance Pharma today announced it has completed the recruitment of patients for the ENHANCE-CHINA (NCT05743075) study, after planned number of patients have been successfully enrolled. The ENHANCE-CHINA study is a phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ensifentrine (Ohtuvayre™) over 24 weeks in adult patients with moderate...
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-girentuximab), is highly accurate in detecting and characterising clear cell...
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction...
